Mobility decreased: FDA reporting patterns
70,673 FDA FAERS reports mention Mobility decreased. 47,779 reports have a serious outcome flag.
Medicines named as suspect
- Etanercept: 11,449 reports
- Adalimumab: 10,599 reports
- Methotrexate: 6,300 reports
- Abatacept: 4,772 reports
- Tocilizumab: 4,745 reports
- Leflunomide: 4,744 reports
- Rituximab: 4,569 reports
- Infliximab: 4,415 reports
- Hydroxychloroquine: 4,406 reports
- Prednisone: 4,061 reports
- Tofacitinib: 3,993 reports
- Sulfasalazine: 3,821 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.